Tenecteplase for stroke patients who recently took blood thinners
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are having an ischemic stroke (a clot blocks blood flow to part of your brain).
- You have taken a type of blood thinner called a DOAC (like apixaban, rivaroxaban, dabigatran, or edoxaban) within the last 48 hours, or you are on a DOAC but don't know when you last took it.
- You can start study treatment within 4.5 hours of when you were last seen normal, or within 4.5 to 24 hours if brain imaging shows a mismatch (meaning there's still salvageable brain tissue).
- Your stroke symptoms are moderate to moderately severe (NIHSS score 4-25), or you have a disabling stroke even with a lower score.
- You have not had any brain bleeding, recent major surgery, severe trauma, or active bleeding. You also must not be pregnant or have certain uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests whether a stronger clot-busting drug (tenecteplase) is safe and works for people who have had a stroke while taking a common blood thinner. If you qualify, you may get this treatment within a few hours of your stroke to help improve recovery.
This trial tests a clot-busting drug called tenecteplase given later than usual (4.5 to 9 hours after stroke symptoms) to people whose MRI shows the stroke may still be reversible. The goal is to see if it helps reduce disability after a stroke.
This trial tests whether a clot-dissolving drug called tenecteplase can improve recovery for people who had a large-vessel ischemic stroke 4.5 to 24 hours earlier and can’t have a mechanical clot removal procedure in time. If you join, you’ll get either tenecteplase or standard medical care, and the study will track your recovery and safety.
This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.
This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.